Figure 2.

Patient-reported (A, B) and parent-reported (C, D) cJADAS10 scores over 5-year follow-up. For oligoarticular arthritis, the following cut-offs were used: ID: ≤1.1, LDA: 1.2–4, MDA: 4.1–12, and HDA: >12. For polyarticular arthritis and other JIA subtypes, the following cut-offs were used: ID: ≤2.5, LDA: 2.6–5, MDA: 5.1–16, and HDA: >16. cJADAS10: clinical 10-joint Juvenile Arthritis Disease Activity Score; continuous users: cohort of patients who enrolled in the registry >1 month after initiating abatacept treatment; HDA: high disease activity; ID: inactive disease; LDA: low disease activity; MDA: moderate disease activity; new users/initiators: cohort of patients who enrolled in the registry ≤1 month after initiating abatacept treatment